Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia (any subtype) or schizoaffective disorder (any subtype)~* Treatment with clozapine for at least 1 year~* Stable dose of clozapine for at least 1 month~* Well established compliance with outpatient medications~* Female participants of non-childbearing potential or of childbearing potential and willing to practice appropriate birth control methods (complete abstinence from sexual intercourse, female sterilization, sterilization of male partner, implants of levonorgestrel, injectable progestogen, oral contraceptives, intrauterine devices, or double barrier methods of contraception using spermicide with either a condom or diaphragm) during the study~Exclusion Criteria:~* Current substance abuse~* Psychiatrically unstable~* Significant medical illness, including severe cardiovascular, hepatic, or renal disease~* History of immunosuppression~* Current or recent radiation or chemotherapy treatment for cancer~* Chronic use of steroids~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will take aripiprazole 15mg/day for 8 weeks.
- 2 (Type: PLACEBO_COMPARATOR): Participants will take placebo for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).